Te‐Chun Hsia

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.2K citations · Full text

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su et al. · The Lancet Oncology · 2012 · 402 citations

Advanced Lung Disease, Medicine, Lung Adenocarcinoma +10

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

Heng‐Huan Lee, Ying‐Nai Wang, Weiya Xia et al. · Cancer Cell · 2019 · 387 citations · Full text

Medicine, Immunology, Glycobiology +5

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

Yi‐Long Wu, Ying Cheng, Jianying Zhou et al. · The Lancet Respiratory Medicine · 2020 · 249 citations

Oncology, Met Amplification, Medicine +10

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Chao‐Hua Chiu, Cheng‐Ta Yang, Jin‐Yuan Shih et al. · Journal of Thoracic Oncology · 2015 · 240 citations

Medicine, Receptor Tyrosine Kinase, Cancer Growth +9